Skip to main content Skip to search Skip to main navigation
News: ICH

ICH: Plans to harmonize with PIC/S and WHO

The International Council for Harmonisation (ICH) has made the Minutes of the ICH Assembly Meeting in Singapore, in November 2019, publicly available. In contrast to the already published press release (we reported), the meeting minutes include new details on the following interesting projects for the GMP area:

  • A closer collaboration with PIC/S on guidelines with relevance to both Regulatory Assessor and  Inspector disciplines is being planned.
    PIC/S would be involved in ICH Guideline work during the public consultation following Step 2band additionally, as an ICH Observer, PIC/S could also request to be part of Plenary Working Parties (PWPs) which would allow an involvement prior to Step 1. The Assembly supported the development of a pilot process.
     
  • On her part, the WHO is planning to cooperate with the ICH.
    The Assembly noted WHO’s considerations shared on the areas of work and complementarities of ICH and WHO which should be considered in ICH Guideline development.
     
  • The Concept Paper outline on the revision of ICH Q9: Quality Risk Management was approved. Both, the ICH Assembly and Management Committee noted capacity constraints in the quality topic area. The starting time for the Q9(R1) guideline will therefore be delayed.
     
  • The Q3C(R8) Maintenance EWG continues its work on the development of Permitted Daily Exposure (PDE) levels for the solvents 2-methyltetrahydrofuran, cyclopentylmethylether and tert-butanol. Q3C(R8) is expected to reach Steps 1 and 2a/b by early 2020.
     
  • The Q3D(R2) Maintenance EWG continues its work on the draft Addendum on cutaneous and transdermal routes of administration.Steps 1 and 2a/b of the Q3D(R2) revision for the cutaneous and transdermal products are expected by early 2020.

The next meeting is scheduled from May 23-27, 2020 in Vancouver, Canada.


Source:

ICH: Meeting Minutes

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next